These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34339275)

  • 1. Building Optimal Three-Drug Combination Chemotherapy Regimens To Eradicate Mycobacterium tuberculosis in Its Slow-Growth Acid Phase.
    Kim S; Yamada WM; Duncanson B; Nole J; Rogers S; Parker S; Bacci M; Mtchedlidze N; Peloquin CA; Louie A; Schmidt S; Drusano GL; Neely MN
    Antimicrob Agents Chemother; 2021 Sep; 65(10):e0069321. PubMed ID: 34339275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination Therapy to Kill Mycobacterium tuberculosis in Its Nonreplicating Persister Phenotype.
    Yamada W; Kim S; Almoslem M; Kim S; Myrick J; Nole J; Duncanson B; Louie A; Peloquin CA; Schmidt S; Drusano GL; Neely M
    Antimicrob Agents Chemother; 2022 Oct; 66(10):e0069522. PubMed ID: 36165631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Building Optimal Three-Drug Combination Chemotherapy Regimens.
    Drusano GL; Neely MN; Kim S; Yamada WM; Schmidt S; Duncanson B; Nole J; Mtchedlidze N; Peloquin CA; Louie A
    Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32900682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Funnel: a Screening Technique for Identifying Optimal Two-Drug Combination Chemotherapy Regimens.
    Drusano GL; Kim S; Almoslem M; Schmidt S; D'Argenio DZ; Myrick J; Duncanson B; Nole J; Brown D; Peloquin CA; Neely M; Yamada W; Louie A
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33199386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Moxifloxacin plus Pretomanid against
    de Miranda Silva C; Hajihosseini A; Myrick J; Nole J; Louie A; Schmidt S; Drusano GL
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid.
    Kim S; Louie A; Drusano GL; Almoslem M; Kim S; Myrick J; Nole J; Duncanson B; Peloquin CA; Scanga CA; Yamada W; Neely M; Schmidt S
    Int J Antimicrob Agents; 2022 Feb; 59(2):106509. PubMed ID: 34958863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity against Mycobacterium tuberculosis of levofloxacin, moxifloxacin and UB-8902 in combination with clofazimine and pretomanid.
    López-Gavín A; Tudó G; Vergara A; Hurtado JC; Gonzalez-Martín J
    Int J Antimicrob Agents; 2015 Nov; 46(5):582-5. PubMed ID: 26421981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis.
    Li SY; Tasneen R; Tyagi S; Soni H; Converse PJ; Mdluli K; Nuermberger EL
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 Study of the Effects of the Tuberculosis Treatment Pretomanid, Alone and in Combination With Moxifloxacin, on the QTc Interval in Healthy Volunteers.
    Li M; Saviolakis GA; El-Amin W; Makhene MK; Osborn B; Nedelman J; Yang TJ; Everitt D
    Clin Pharmacol Drug Dev; 2021 Jun; 10(6):634-646. PubMed ID: 33378139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates.
    Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD
    J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of Moxifloxacin against
    Louie A; Duncanson B; Myrick J; Maynard M; Nole J; Brown D; Schmidt S; Neely M; Scanga CA; Peloquin C; Drusano GL
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.
    Deshpande D; Srivastava S; Nuermberger E; Pasipanodya JG; Swaminathan S; Gumbo T
    Clin Infect Dis; 2016 Nov; 63(suppl 3):S88-S94. PubMed ID: 27742639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moxifloxacin Replacement in Contemporary Tuberculosis Drug Regimens Is Ineffective against Persistent Mycobacterium tuberculosis in the Cornell Mouse Model.
    Liu Y; Pertinez H; Davies GR; Gillespie SH; Coates AR; Hu Y
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose Fractionation of Moxifloxacin for Treatment of Tuberculosis: Impact of Dosing Interval and Elimination Half-Life on Microbial Kill and Resistance Suppression.
    Drusano GL; Rogers S; Brown D; Peloquin CA; Neely M; Yamada W; Kim S; Almoslem M; Schmidt S; Louie A
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33468465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Linezolid plus Bedaquiline against Mycobacterium tuberculosis in Log Phase, Acid Phase, and Nonreplicating-Persister Phase in an
    de Miranda Silva C; Hajihosseini A; Myrick J; Nole J; Louie A; Schmidt S; Drusano GL
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
    Gumbo T; Louie A; Deziel MR; Parsons LM; Salfinger M; Drusano GL
    J Infect Dis; 2004 Nov; 190(9):1642-51. PubMed ID: 15478070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model.
    Drusano GL; Sgambati N; Eichas A; Brown DL; Kulawy R; Louie A
    mBio; 2010 Aug; 1(3):. PubMed ID: 20802826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.
    Diacon AH; Dawson R; von Groote-Bidlingmaier F; Symons G; Venter A; Donald PR; van Niekerk C; Everitt D; Winter H; Becker P; Mendel CM; Spigelman MK
    Lancet; 2012 Sep; 380(9846):986-93. PubMed ID: 22828481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics.
    Srivastava S; Deshpande D; Magombedze G; van Zyl J; Cirrincione K; Martin K; Bendet P; Berg A; Hanna D; Romero K; Hermann D; Gumbo T
    J Antimicrob Chemother; 2020 Feb; 75(2):392-399. PubMed ID: 31713607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.